Research Article
Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease
Table 3
Results of the Cox regression analysis of type of drug insurance coverage and time to first anti-TNF dose.
| Characteristic | Hazard ratio | 95% CI |
| Public drug coverage | 0.67 | 0.45–0.95 | Age | 1.00 | 0.98–1.03 | Age at IBD diagnosis | 1.00 | 0.98–1.03 | Female gender | 1.10 | 0.78–1.56 | Crohn’s disease | 1.46 | 1.00–2.12 | Immunomodulator use | 1.16 | 0.82–1.65 | Steroid dependent or refractory disease | 1.02 | 0.74–1.41 | IBD of aggressive behaviour | 0.81 | 0.55–1.18 | Copay scheme use | 0.74 | 0.37–1.48 |
|
|